TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14696522

Group type: EXPERIMENTAL
Intervention: TachoComb dressing (collagen mesh covered by fibrin glue) applied in 29 cases
Number of subjects: 54

Group type: COMPARATOR
Intervention: Gas compresses (control group) used in 25 patients
Number of subjects: 54
Study: 11049913

Group type: EXPERIMENTAL
Intervention: Tramadol 2.5 mg/kg (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tramadol 1.25 mg/kg + lysine acetyl salicylate 12.5 mg/kg (Group 2)
Number of subjects: 50
Study: 9284852

Group type: EXPERIMENTAL
Intervention: Milrinone (reversed microdialysis)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Theophylline (reversed microdialysis)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Compound 48/80 (reversed microdialysis)
Number of subjects: 24
Study: 1329673

Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg injections three times a week for six weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Thymopentin (continued for an additional six weeks in group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (control group B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Thymopentin treatment
Number of subjects: 16
Study: 3919557

Group type: EXPERIMENTAL
Intervention: Bepridil once daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31605792

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 106

Group type: COMPARATOR
Intervention: Comparator (EGFR tyrosine kinase inhibitors)
Number of subjects: 106
Study: 31058358

Group type: EXPERIMENTAL
Intervention: Higher upper-limbs absolute strength
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Higher lower-limbs relative-to-weight strength
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Higher speed-agility
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Higher cardiorespiratory fitness levels
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sedentary time and other PA intensities
Number of subjects: 79
Study: 30442122

Group type: COMPARATOR
Intervention: Current practice of BP lowering therapy
Number of subjects: 62194

Group type: EXPERIMENTAL
Intervention: Intermediate risk threshold for BP lowering therapy
Number of subjects: 62194

Group type: EXPERIMENTAL
Intervention: High risk threshold for BP lowering therapy
Number of subjects: 62194
Study: 26369526

Group type: COMPARATOR
Intervention: 40 mg basiliximab with cyclosporine (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 80 mg basiliximab with cyclosporine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 80 mg basiliximab with everolimus (CNI-free)
Number of subjects: 16
Study: 24481719

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 123

Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 123
Study: 22682340

Group type: EXPERIMENTAL
Intervention: Non-invasive metric parameters (age, weight, height, body surface area, body mass index)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Measurement of red cell volume after 4 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Measurement of plasma volume
Number of subjects: 46
Study: 19183087

Group type: EXPERIMENTAL
Intervention: Self-management
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oral amitriptyline (10-20 mg/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Topical triamcinolone plus oral amitriptyline (10-20 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study: 17937333

Group type: EXPERIMENTAL
Intervention: Screening arm (PSA analysis and sextant prostate biopsy)
Number of subjects: 4278

Group type: COMPARATOR
Intervention: Control arm (no PSA analysis or biopsy)
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 4278

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 4278
Study: 15823767

Group type: EXPERIMENTAL
Intervention: Mix 75/25 plus metformin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Insulin glargine plus metformin
Number of subjects: 105
Study: 11223660

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (CV) of atrial fibrillation after at least 3 weeks of effective anticoagulation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (CV) of atrial fibrillation
Number of subjects: 29
Study: 9844163

Group type: EXPERIMENTAL
Intervention: High-voltage pulsed current electrical stimulation
Number of subjects: 132
Study: 7818782

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fetal cardiac sampling in the left or right uterine horn
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsampled uterine horns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fetal hematologic parameters
Number of subjects: 0
Study: 2732023

Group type: EXPERIMENTAL
Intervention: Topical timolol maleate 0.5%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 1056055

Group type: EXPERIMENTAL
Intervention: Isokinetic training (fast speed)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isokinetic training (slow speed)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 31677292

Group type: EXPERIMENTAL
Intervention: Partial-body cryotherapy (PBC)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Passive control (CON)
Number of subjects: 28
Study: 31039774

Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Referred hands
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Involvement of additional interphalangeal joints
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Referred hand pain
Number of subjects: 180
Study: 28024698

Group type: EXPERIMENTAL
Intervention: Surgical resection (simulated cohort size of 16)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Surgical resection (simulated cohort size of 27)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Surgical resection (simulated cohort size of 515)
Number of subjects: 749
Study: 25933709

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 430

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 430
Study: 24590961

Group type: EXPERIMENTAL
Intervention: Standardized user fee intervention
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Free services
Number of subjects: 47

Group type: COMPARATOR
Intervention: Current cost-sharing systems (Control)
Number of subjects: 47
Study: 21599945

Group type: EXPERIMENTAL
Intervention: Systematic voiding programme
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Systematic voiding programme plus supported implementation
Number of subjects: 780

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 780
Study: 19341544

Group type: EXPERIMENTAL
Intervention: Immediate blood-test ordering
Number of subjects: 325

Group type: COMPARATOR
Intervention: Postponed blood-test ordering (after 4 weeks)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Expanded test set
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Limited test set
Number of subjects: 325
Study: 16958189

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 0
Study: 12519316

Group type: EXPERIMENTAL
Intervention: Repeat OGTT at 10-year follow-up
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Subjects without diabetes at baseline (n = 517)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of diabetes
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of baseline variables
Number of subjects: 563
Study: 10852983

Group type: COMPARATOR
Intervention: Prednisone (60 mg/day) alone (group A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day) combined with cyclical etidronate (group B)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison between group A and group B at day 5
Number of subjects: 14
Study: 9612103

Group type: EXPERIMENTAL
Intervention: Metronidazole and gentamicin (Group A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Metronidazole and ciprofloxacin (Group B)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Metronidazole and cefotaxime (Group C)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cefotaxime and metronidazole combination
Number of subjects: 128

Group type: COMPARATOR
Intervention: Comparison between Group A and Group C
Number of subjects: 128

Group type: COMPARATOR
Intervention: Comparison among all groups
Number of subjects: 128
Study: 8436000

Group type: EXPERIMENTAL
Intervention: Slimline device
Number of subjects: 996

Group type: COMPARATOR
Intervention: Standard model
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: First-time IUD users
Number of subjects: 996

Group type: COMPARATOR
Intervention: Former users
Number of subjects: 996
Study: 3094172

Group type: EXPERIMENTAL
Intervention: Thiamphenicol (single oral dose)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lymecycline (two 1.5-g oral doses taken 12 hr apart)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Thiamphenicol (in penicillinase-producing Neisseria gonorrhoeae group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lymecycline (in penicillinase-producing Neisseria gonorrhoeae group)
Number of subjects: 75
Study: 30365202

Group type: EXPERIMENTAL
Intervention: Cebranopadol (200–1,000 μg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Morphine prolonged release (PR) (≤120 mg daily)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cebranopadol and Morphine PR
Number of subjects: 126
Study: 28986703

Group type: EXPERIMENTAL
Intervention: TRV027 1 mg/h
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: TRV027 (lower doses)
Number of subjects: 618
Study: 26908002

Group type: EXPERIMENTAL
Intervention: dispatcher-assisted compression-only CPR (DACO-CPR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: dispatcher-assisted full CPR with rescue ventilation (DAF-CPR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: unassisted CPR (U-CPR)
Number of subjects: 60
Study: 24214165

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention (30 sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 32
Study: 22127229

Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention with TEE assessment at baseline, months 1, 3, and 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention with TEE assessment at baseline, months 3 and 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention with TEE assessment at baseline, months 1 and 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention with TEE assessment at baseline and month 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie restriction intervention
Number of subjects: 0
Study: 20810311

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17492582

Group type: EXPERIMENTAL
Intervention: SNRIs (selective noradrenaline reuptake inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of behavior therapy and SSRIs (selective serotonin reuptake inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding an SSRI, an SNRI, or an atypical antipsychotic to an SSRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNRIs
Number of subjects: 0
Study: 12633543

Group type: EXPERIMENTAL
Intervention: ACE inhibitor captopril
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 10687671

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 272

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 272

Group type: COMPARATOR
Intervention: Simvastatin 10 mg
Number of subjects: 272
Study: 9181900

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg p.o. daily for six months
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg p.o. daily for fourteen days, then reduced to 10 mg for a total treatment period of six months
Number of subjects: 62
Study: 8398713

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg qid for 5 days with each course of chemotherapy)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (chemotherapy without verapamil)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 226
Study: 3299394

Group type: COMPARATOR
Intervention: ferrous sulphate (100 mg/day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ferritin (80 mg/day as Fe3+)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: combination of ferritin (80 mg Fe3+/day), folinic acid and vitamin B12 coenzyme
Number of subjects: 54
Study: 30290801

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 2475

Group type: COMPARATOR
Intervention: Other ICS
Number of subjects: 2475

Group type: COMPARATOR
Intervention: No ICS
Number of subjects: 2475
Study: 25772478

Group type: EXPERIMENTAL
Intervention: Weight management intervention for 12 weeks
Number of subjects: 0
Study: 24851692

Group type: EXPERIMENTAL
Intervention: 20 mg rt-PA with catheter-directed thrombolysis
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 10 mg rt-PA with catheter-directed thrombolysis
Number of subjects: 84

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 84
Study: 22480663

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50 mg administered 1 hour before each exposure session
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo administered 1 hour before each exposure session
Number of subjects: 67
Study: 20591781

Group type: EXPERIMENTAL
Intervention: Packable resin-based composite restoration
Number of subjects: 20
Study: 19064843

Group type: EXPERIMENTAL
Intervention: Ultrasound biomicroscopy (UBM) before and after laser iridotomy for newly diagnosed PACG and APAC patients; UBM at enrollment for treated PACG patients.
Number of subjects: 82
Study: 15789288

Group type: EXPERIMENTAL
Intervention: IRES-3
Number of subjects: 453
Study: 12865480

Group type: EXPERIMENTAL
Intervention: Functionally oriented endurance and resistance exercise training (32 weeks, 5 days a week, 2 hours per day)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 190
Study: 10510162

Group type: EXPERIMENTAL
Intervention: 8 micromol min‐1 N‐monomethyl L‐arginine (L‐NMMA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8787171

Group type: EXPERIMENTAL
Intervention: Cladribine (new immunosuppressive drug)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 2005075

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1168
Study: 6404577

Group type: EXPERIMENTAL
Intervention: Tiapamil (200 mg t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30578459

Group type: EXPERIMENTAL
Intervention: High FORTA score (cut-off 3)
Number of subjects: 409
Study: 27943391

Group type: EXPERIMENTAL
Intervention: Reprogram group (n = 52, 16%)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Magnet group (n = 51, 15%)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: No change group (n = 228, 69%)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Thoracic cases
Number of subjects: 331

Group type: COMPARATOR
Intervention: Head/neck cases
Number of subjects: 331

Group type: COMPARATOR
Intervention: Upper extremity cases
Number of subjects: 331

Group type: COMPARATOR
Intervention: Abdominal cases above iliac crest
Number of subjects: 331

Group type: COMPARATOR
Intervention: Procedures below iliac crest
Number of subjects: 331
Study: 26524699

Group type: EXPERIMENTAL
Intervention: 8-week CCR based on Nordic walking training (five times weekly) at 40-70% of maximal heart rate
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 111
Study: 25516028

Group type: EXPERIMENTAL
Intervention: stretching+educational DVD
Number of subjects: 72

Group type: COMPARATOR
Intervention: stretching+cognitive training
Number of subjects: 72

Group type: COMPARATOR
Intervention: aerobic+educational DVD
Number of subjects: 72

Group type: COMPARATOR
Intervention: aerobic+cognitive training
Number of subjects: 72
Study: 22966414

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Kaneka QH ubiquinol; 300 mg per day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19412016

Group type: EXPERIMENTAL
Intervention: Bioresorbable plate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium plate
Number of subjects: 40
Study: 17218573

Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 26
Study: 12838055

Group type: EXPERIMENTAL
Intervention: Fifty units per kilogram of recombinant human erythropoietin
Number of subjects: 45
Study: 11156217

Group type: EXPERIMENTAL
Intervention: GMK vaccine (30 microg of G(M2)) and GDK (various doses)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GDK (30 or 70 microg of G(D2))
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GDK (various doses)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GDK (highest dose level)
Number of subjects: 31
Study: 8891621

Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gentamicin 80 mg
Number of subjects: 20
Study: 2006355

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 6625729

Group type: EXPERIMENTAL
Intervention: 1 X 40 mg kg‐1 (Group A)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: 2 X 20 mg kg‐1 (Group B)
Number of subjects: 431

Group type: COMPARATOR
Intervention: 1 X 40 mg kg‐1 (Camps)
Number of subjects: 431
Study: 30106837

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) in VFO patients (n=91)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Delayed enteral nutrition (started after 48 hours) in non-VFO patients (n=108)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Delayed enteral nutrition (started after 48 hours) in VFO patients (n=88)
Number of subjects: 286
Study: 31301057

Group type: EXPERIMENTAL
Intervention: Core stability exercise training (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Treadmill exercise program (Group C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional physical therapy intervention strategies (Group A)
Number of subjects: 45
Study: 28708216

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) ceftazidime prior to colonoscopy (Group A)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (Group B)
Number of subjects: 93
Study: 26043222

Group type: EXPERIMENTAL
Intervention: Experimental group (participated in a football match)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (participated only in measurements and practices)
Number of subjects: 34
Study: 24201237

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 21701528

Group type: EXPERIMENTAL
Intervention: TRA/TIM BAK-free
Number of subjects: 388

Group type: COMPARATOR
Intervention: TRA/TIM
Number of subjects: 388
Study: 19433694

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxazosin mesylate
Number of subjects: 0
Study: 16675323

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP), 50, 100, 200, and 400 microg/d, each for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16124647

Group type: EXPERIMENTAL
Intervention: BCG-PSN
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 10578485

Group type: EXPERIMENTAL
Intervention: Green vegetables (4th quartile)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Tomatoes
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Beans/lentils/nuts
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Cruciferous vegetables (3rd quartile)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Fruit (4th quartile)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Refined-grain bread (4th quartile)
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Whole-grain breakfast cereals
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Cryptoxanthin (4th quartile)
Number of subjects: 1253
Study: 8909626

Group type: EXPERIMENTAL
Intervention: SMART Talk intervention (multimedia, computer-based violence-prevention program)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group (no access to SMART Talk during the intervention period)
Number of subjects: 558
Study: 1812311

Group type: EXPERIMENTAL
Intervention: Health contract intervention
Number of subjects: 69
Study: 6416861

Group type: EXPERIMENTAL
Intervention: 1-norgestrel (120 micrograms)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Progesterone (300 mg)
Number of subjects: 26
Study: 30880522

Group type: COMPARATOR
Intervention: Patient-selected music (Pandora®)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Preselected music (Mozart)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: No music (control)
Number of subjects: 150
Study: 30778667

Group type: EXPERIMENTAL
Intervention: 6% L-ascorbate-2-phosphate trisodium salt (APS) in test lotion (TL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo lotion (PL)
Number of subjects: 27
Study: 29395188

Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg daily for 3 weeks)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (daily for 3 weeks)
Number of subjects: 104